508 related articles for article (PubMed ID: 7586606)
1. Vitamin D status in primary hyperparathyroidism in India.
Harinarayan CV; Gupta N; Kochupillai N
Clin Endocrinol (Oxf); 1995 Sep; 43(3):351-8. PubMed ID: 7586606
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.
Brossard JH; Garon J; Lepage R; Gascon-Barré M; D'Amour P
Bone Miner; 1993 Oct; 23(1):15-26. PubMed ID: 8274876
[TBL] [Abstract][Full Text] [Related]
3. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism.
Ozbey N; Erbil Y; Ademoğlu E; Ozarmağan S; Barbaros U; Bozbora A
World J Surg; 2006 Mar; 30(3):321-6. PubMed ID: 16467981
[TBL] [Abstract][Full Text] [Related]
4. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery.
Räkel A; Brossard JH; Patenaude JV; Albert C; Nassif E; Cantor T; Rousseau L; D'Amour P
Clin Endocrinol (Oxf); 2005 Jun; 62(6):721-7. PubMed ID: 15943835
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.
Moosgaard B; Vestergaard P; Heickendorff L; Melsen F; Christiansen P; Mosekilde L
Clin Endocrinol (Oxf); 2005 Nov; 63(5):506-13. PubMed ID: 16268801
[TBL] [Abstract][Full Text] [Related]
6. Very low or undetectable intact parathyroid hormone levels in patients with surgically verified parathyroid adenomas.
Bhadada SK; Cardenas M; Bhansali A; Mittal BR; Behera A; Chanukya GV; Nahar U; Rao DS
Clin Endocrinol (Oxf); 2008 Sep; 69(3):382-5. PubMed ID: 18284640
[TBL] [Abstract][Full Text] [Related]
7. Brown tumor due to primary hyperparathyroidism in a familial case: a case report.
Diao Z; Zhang J; Zhao J; Sun W; Pu Z
BMC Endocr Disord; 2023 Oct; 23(1):214. PubMed ID: 37807045
[TBL] [Abstract][Full Text] [Related]
8. Influence of age and gender on presentation of symptomatic primary hyperparathyroidism.
Shah VN; Bhadada SK; Bhansali A; Behera A; Mittal BR; Bhavin V
J Postgrad Med; 2012; 58(2):107-11. PubMed ID: 22718053
[TBL] [Abstract][Full Text] [Related]
9. Two cases of spontaneous remission of primary hyperparathyroidism due to auto-infarction: different management and their outcomes.
Novodvorsky P; Hussein Z; Arshad MF; Iqbal A; Fernando M; Munir A; Balasubramanian SP
Endocrinol Diabetes Metab Case Rep; 2019 May; 2019():. PubMed ID: 31063971
[TBL] [Abstract][Full Text] [Related]
10. Large parathyroid adenomas: Potential mechanisms to reconcile adenoma size and disease phenotype.
Bhan A; Athimulam S; Kumari P; Pal R; Bhadada SK; Cook BC; Qiu S; Rao SD
Front Endocrinol (Lausanne); 2023; 14():1009516. PubMed ID: 36817587
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory profile of primary hyperparathyroidism in India.
Priya G; Jyotsna VP; Gupta N; Chumber S; Bal CS; Karak AK; Seth A; Ammini AC
Postgrad Med J; 2008 Jan; 84(987):34-9. PubMed ID: 18230749
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
14. [Surgical therapy concept in primary hyperparathyroidism].
Rusterholz D; Müller W
Schweiz Med Wochenschr Suppl; 2000; 116():62S-65S. PubMed ID: 10780075
[TBL] [Abstract][Full Text] [Related]
15. Primary hyperparathyroidism masked by antituberculous therapy-induced vitamin D deficiency.
Kovacs CS; Jones G; Yendt ER
Clin Endocrinol (Oxf); 1994 Dec; 41(6):831-6: discussion 837-8. PubMed ID: 7889622
[TBL] [Abstract][Full Text] [Related]
16. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency.
Isidro ML; Ruano B
Endocrine; 2009 Oct; 36(2):305-10. PubMed ID: 19598008
[TBL] [Abstract][Full Text] [Related]
17. Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency.
Das G; Eligar V; Govindan J; Bondugulapati LN; Okosieme O; Davies S
Ann Clin Biochem; 2015 Jul; 52(Pt 4):462-9. PubMed ID: 25468998
[TBL] [Abstract][Full Text] [Related]
18. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
[TBL] [Abstract][Full Text] [Related]
19. Increased prevalence of primary hyperparathyroidism in treated breast cancer.
Fierabracci P; Pinchera A; Miccoli P; Conte PF; Vignali E; Zaccagnini M; Marcocci C; Giani C
J Endocrinol Invest; 2001 May; 24(5):315-20. PubMed ID: 11407650
[TBL] [Abstract][Full Text] [Related]
20. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region.
Raef H; Ingemansson S; Sobhi S; Sultan A; Ahmed M; Chaudhry M
J Endocrinol Invest; 2004 Oct; 27(9):807-12. PubMed ID: 15648543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
